

Dr. Angèle Maki is a business development executive with thirteen years of deal-making experience spanning small biotech and big pharma. She is currently a Director of Business Development at 23andMe where she leads sourcing and negotiation of licensing transactions and R&D collaborations with biotech and pharma. Prior to 23andMe, Angèle was an Associate Director in Genentech's Partnering group where she was responsible for developing and executing technology licensing strategies for human genetics, antibody engineering, small molecule drug discovery, and other research technologies. Angèle received a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at the Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg, in Canada.